宝洛克萨维尔马博西尔的现实世界不成比例分析:营销后药监数据
Jie Zhou1, Junchang Ye1, Maohua Chen2
1Department of Pharmacy, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhangzhou, People's Republic of China.
Expert opinion on drug safety
|September 5, 2024
概括
流感药Baloxavir marboxil在安全性分析中显示了肺炎和等新的不良事件. 医疗保健提供者应该监测除了药物之外的这些潜在风险.
科学领域:
- 药监和药物安全 药监和药物安全
- 传染病治疗方法 传染病治疗方法
- 临床药理学 临床药理学
背景情况:
- 巴洛克萨维尔马博西尔是一种用于治疗和预防流感的新型封顶依赖性内核酶抑制剂.
- 该药物于2018年获得批准,其在大量人群中的长期安全性仍在调查中.
- 了解现实世界的不良事件对于患者安全至关重要.
研究的目的:
- 评估与 baloxavir 相关的不良事件 (AEs).
- 通过FDA不良事件报告系统 (FAERS) 的数据挖掘,识别潜在的新安全信号.
主要方法:
- 在2018年3月至2023年6月的FAERS数据上使用了不成比例分析.
- 使用的信号量化技术:ROR,PRR,BCPNN和MGPS. 使用的信号量化技术:ROR,PRR,BCPNN和MGPS.
- 为强大的AE信号检测提供标准化数据.
主要成果:
- 在20个器官系统类别中确定了49个与巴洛克萨维尔相关的重要首选术语.
- 检测到新的不良事件信号,这些信号未在当前的FDA标签上列出.
- 最重要的新出现的AE包括肺炎,意识丧失,狂肌溶解,和脑病变.
结论:
- 临床使用巴洛克萨维尔需要对新发现的不良事件保持警.
- 建议对肺炎,神经事件和肝脏异常等信号进行监测.
- 确保患者安全需要意识到产品标签之外的新出现的AE配置文件.
相关概念视频
Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
104
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
104
Analysis of Population Pharmacokinetic Data
240
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
240
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
227
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
227
Bioequivalence: Overview
949
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
949
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
51
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
51


